Overview Omeros Corporation (Omeros, the Company or we) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Our complement-targeted product, product candidates, and therapeutic programs are primarily focused on diseases and disorders associated with the lectin and/...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001437749-26-010636 | EDGAR | 68K words |
| 2025-03-31 | 2024-12-31 | 0001437749-25-010216 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001437749-24-010416 | EDGAR | — |
| 2023-03-13 | 2022-12-31 | 0001558370-23-003575 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001558370-22-002582 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001558370-21-002177 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001558370-20-001891 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001628280-19-002324 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001285819-18-000003 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001285819-17-000004 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001437749-25-034826 | EDGAR | 30K words |
| 2025-08-14 | 2025-06-30 | 0001437749-25-026933 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001437749-25-017213 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001437749-24-034903 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001437749-24-025181 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001437749-24-017047 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001437749-23-031250 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014095 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008814 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017153 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001558370-22-012884 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001558370-22-008120 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001437749-26-010634 | EDGAR | 5K words |
| 2026-01-07 | 0001437749-26-000820 | EDGAR | — |
| 2025-12-29 | 0001437749-25-038758 | EDGAR | — |
| 2025-12-01 | 0001437749-25-036507 | EDGAR | — |
| 2025-11-13 | 0001437749-25-034824 | EDGAR | — |
| 2025-10-15 | 0001437749-25-030968 | EDGAR | — |
| 2025-08-14 | 0001437749-25-026931 | EDGAR | — |
| 2025-07-25 | 0001104659-25-070554 | EDGAR | — |
| 2025-07-02 | 0001437749-25-021959 | EDGAR | — |
| 2025-05-15 | 0001437749-25-017211 | EDGAR | — |
297 total filings indexed. 265 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001285819 |
| Ticker | OMER |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | WA |
| Website | https://www.omeros.com |
| Listed | 2009-10-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report